Shep, others. More info on wound care...
Be nice to know what Doc Arrow said about MAGN. I called Wedbush but declined to spring for $1000 or an A/C. Did not see this linked to MAGN news.
First 3 Biotech Wound Care Products Launched in the U.S., Refocusing
Attention and Expectations on Wound Care, Analyst Says
LOS ANGELES, Jan. 8 /PRNewswire/ -- The following is being issued by Wedbush Morgan Securities, a member of the National Association of Securities Dealers, CRD Number 877. Wedbush Morgan Securities is also a member of the New York Stock Exchange:
The first three wound care biotechnology products have launched in the U.S., re-focusing attention on this market as ''a major target of biotechnology companies,'' according to an analyst covering the
sector. The entire wound care biotechnology sector has been broken down, described, and rated in a newly-released research report.
Dr. Alexander Arrow, Vice President, Research at Wedbush Morgan Securities in Los Angeles, has issued the fourth edition of his popular report describing companies competing in each of eleven
sub-sectors of the wound care market.
The markets described include the diabetic foot ulcer market, the severe burn market, the emergency room wound-closing glue market, and eight others.
The product launches described, Chiron's ''Regranex'' for foot ulcers, Organogenesis' ''Apligraf'' for venous ulcers, and Closure Medical's ''Dermabond'' for skin lacerations, have drawn the attention of large companies and large investors to wound care. Five other companies are set to launch new internal wound glues in 1999. The report analyzes the relative strengths and weaknesses of each wound care company.
The report then goes on to ''rank'' each company's position in its market according to three parameters: the strength of its product, the stage of its development, and the effectiveness of its distribution system. The report also offers investment recommendations on four companies on the Wedbush Morgan wound care research list.
Dr. Arrow's report highlights and compares a total of 38 companies (28 public and 10 private) in this industry segment. The public wound care companies included are:
Advanced Tissue Sciences (ATIS), BioSpecifics (BSTC), Carrington Laboratories (CARN), Chiron Corporation (Nasdaq:CHIR - news), Closure Medical (CLSR), Cohesion Technologies (CSON), Cryolife (CRY), Curative Health Services (CURE), Cypros Pharmaceuticals (CYP), Datascope Corporation (Nasdaq:DSCP - news).
Also, Derma Sciences (DSCI), Focal (FOCL), Fusion Medical Technologies (FSON), Genzyme Tissue Repair (Nasdaq:GENZL - news), Gliatech (GLIA), Human Genome Sciences (HGSI), Integra LifeSciences (IART), Kensey Nash (KNSY), Life Medical Sciences (CHAI), LifeCell Corporation (LIFC).
Also, Lifecore Biomedical (LCBM), Magainin Pharmaceuticals (MAGN), Organogenesis (ORG), Ortec International (ORTC), Perclose (PERC), ProCyte (PRCY), ThermoGenesis (KOOL), and Vitex (VITX).
Larger companies with collaborations in wound care detailed in the report include:
Baxter (BAX), Bristol-Myers Squibb (BMS), Johnson & Johnson (JNJ), Novartis (NVTSY), Tyco (TYC), 3M Corporation (MMM).
SOURCE: Wedbush Morgan Securities |
